

Meeting Report

Meeting of the Greater Mekong Subregion (GMS) Therapeutic Efficacy Study (TES) Network



20–21 May 2014
Ha Noi, Viet Nam



WPR/DCC/MVP(03)/2014
RS/2014/GE/28(VNM)

English only

REPORT

MEETING OF THE GREATER MEKONG SUBREGION (GMS) THERAPEUTIC EFFICACY STUDY (TES) NETWORK

Convened by:

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC

Ha Noi, Viet Nam
20–21 May 2014

Not for sale

Printed and distributed by:

World Health Organization
Regional Office for the Western Pacific
Manila, Philippines

July 2015

NOTE

The views expressed in this report are those of the participants of the Meeting of the Greater Mekong Subregion (GMS) Therapeutic Efficacy Study (TES) Network and do not necessarily reflect the policies of the conveners.

This report has been prepared by the World Health Organization Regional Office for the Western Pacific for Member States in the Region and for those who participated in the Meeting of the Greater Mekong Subregion (GMS) Therapeutic Efficacy Study (TES) Network in Ha Noi, Viet Nam from 20 to 21 May 2014.

TABLE OF CONTENTS

ACKNOWLEDGEMENTS

ACRONYMS

SUMMARY

INTRODUCTION 1

PROCEEDINGS 3

COUNTRY PLANS..... 20

CONCLUSIONS..... 26

RECOMMENDATIONS 27

ANNEXES 29

Annex 1: Agenda

Annex 2: List of participants

Annex 3: ERAR Action plan for Antimalarial Resistance monitoring in the GMS and BBINS

Annex 4: Efficacy of ACTs against *P. falciparum*, Greater Mekong Subregion, 2008 to 2013

Keywords:

Therapeutics / Antimalarials / Malaria – prevention and control / Mekong Valley

ACKNOWLEDGEMENTS

The meeting to review and plan therapeutic efficacy studies (TES) to monitor *P. falciparum* and *P. vivax* resistance to antimalarial drugs in the Greater Mekong Subregion (GMS) was organized in collaboration with the WHO Regional Offices for South-East Asia and the Western Pacific, the Global Malaria Programme at WHO headquarters, and the WHO Emergency Response to Artemisinin Resistance (ERAR) Office in Phnom Penh, Cambodia. The meeting was co-hosted by the National Institute of Malariology, Parasitology and Entomology of the Ministry of Health, Viet Nam, and the WHO country office in Ha Noi, Viet Nam.

The organizers of the meeting thank all facilitators for their technical inputs and assistance in monitoring and ensuring the quality of TES implementation in the Mekong countries. The organizers also thank all country programme managers, principal investigators and representatives from Mekong countries for their involvement in the proper and timely implementation of TES country proposals planned since 2007 and their continued commitment and interest in the *in vivo* TES Greater Mekong Subregion Network. WHO wishes to acknowledge the technical support from partners and financial support from the United States Agency for International Development, President's Malaria Initiative (USAID-PMI) to implement TES. The Organization also expresses appreciation for the support provided by the Bill and Melinda Gates Foundation (BMGF) and Australia's Department of Foreign Affairs and Trade (DFAT) in convening this meeting and for their continuous and generous support for the GMS TES Network.

ABBREVIATIONS

ACPR	Adequate Clinical and Parasitological Response
ACT	Artemisinin combination therapy
AL	Artemether-Lumefantrine (Coartem™)
AM	Artemether
AS	Artesunate
AS+SP	Artesunate + Sulfadoxine-pyrimethamine
AS+MEF	Artesunate - Mefloquine
AS-PYR	Artesunate – Pyronaridine (Pyramax™)
BBINS	Bangladesh, Bhutan, India, Nepal, Sri Lanka
CNM	Cambodian National Centre for Parasitology, Entomology and Malaria Control
CQ	Chloroquine
DFAT	Australian Department of Foreign Affairs and Trade
DHA-PIP	Dihydroartemisinin-Piperaquine
ERAR	Emergency Response to Artemisinin Resistance
GFATM	The Global Fund to Fight AIDS, Tuberculosis and Malaria
LFU	loss to follow-up
LPF	late parasitological failure
MEF	Mefloquine
NIMPE	National Institute of Malariology, Parasitology and Entomology
NMCP	National Malaria Control Programme
PCE	Parasite clearance estimator
PMI	President's Malaria Initiative
RAI	Regional Artemisinin Initiative
RDT	rapid diagnostic test
SP	Sulfadoxine-pyrimethamine (Fansidar)
TES	therapeutic efficacy studies
UNOPS	United Nations Office for Project Services
USAID	United States Agency for International Development
WHO	World Health Organization
WTH	withdrawal of patients

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27842

